Thursday, July 10, 2014





FDA panel backs inhaler drug for lung disease


April 17. 2013 3:34PM
Associated Press

Story Tools
PrintPrint | E-MailEMail | SaveSave | Hear Generate QR Code QR
Send to Kindle


(AP) A panel of respiratory experts has voted in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravence for treating chronic lung disease.


A majority of Food and Drug Administration panelists voted that the Breo Ellipta inhaler is safe and effective for long-term use and to control flare ups in patients with chronic obstructive pulmonary disorder.


The FDA is not required to follow the group's recommendation, though it often does.


The ailment, often called smoker's cough, can cause a number of breathing problems, including chronic bronchitis and emphysema.


Breo is a combination of two respiratory drugs that help to open lung airways and reduce swelling. The combination drug is designed to be used with the Ellipta inhaler device.


Associated Press


Comments
comments powered by Disqus Commenting Guidelines
Poll
Mortgage Minute


Search for New & Used Cars

Make 
Model
 
Used New All
 

Search Times Leader Classifieds to find just the home you want!

Search Times Leader Classifieds to find just what you need!

Search Pet Classifieds
Dogs Cats Other Animals



Social Media/RSS
Times Leader on Twitter
Times Leader on Youtube
Times Leader on Google+
The Times Leader on Tumblr
The Times Leader on Pinterest
Times Leader RSS Feeds